CJC-1295 + Ipamorelin

CJC-1295 + Ipamorelin — Research Compound

CJC-1295 + Ipamorelin is a synergistic combination of two distinct growth hormone secretagogues that target the hypothalamic-pituitary axis. CJC-1295 acts as a synthetic analogue of Growth Hormone Releasing Hormone (GHRH) with an extended half-life, while Ipamorelin functions as a selective ghrelin receptor agonist. This combination is studied for its dual-action approach, investigating how simultaneous receptor activation influences endogenous growth hormone production and downstream cellular repair.

Findings from early-stage clinical trials have reported:

• Sustained increases in plasma growth hormone and insulin-like growth factor 1 (IGF-1) levels observed in research subjects
  
• Improvements in nitrogen retention and protein synthesis rates reported in experimental models
  
• Reductions in adipose tissue mass alongside maintained lean muscle volume noted in-vivo
  
• Enhanced recovery times for connective tissue and skeletal muscle following injury reported in research studies

Researchers study the combination of CJC-1295 and Ipamorelin to explore the biological limits of growth hormone modulation. By utilising two different pathways—GHRH receptor agonism and ghrelin receptor targeting—this compound allows for the investigation of synergistic effects on metabolism and tissue regeneration. It serves as a vital tool for understanding neuroendocrine feedback loops and the potential for optimised physiological recovery.

Available Formats:
This compound is available as a vial of lyophilised powder, or can be ordered in a disposable pen, a reusable pen, or a cartridge for an existing reusable pen system.

Used solely for in vitro experiments and cannot be:

• Used in clinical trials involving humans
• Administered to humans as part of an experiment or investigation
• Supplied to another party for human investigational use